Cardioprotective effects of thiazolidinediones, peroxisome proliferator-activated receptor-gamma agonists.
Greater myocardial injury in response to ischemia/ reperfusion (I/R) and increased incidence of congestive heart failure and death in noninsulin-dependent diabetes mellitus, or type 2 diabetes, patients has been clearly identified. Thiazolidinediones (TZDs), peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists, act as insulin sensitizers and are a novel class of oral antidiabetic drugs. An emerging body of evidence, mainly from preclinical studies, suggest that TZDs protect the heart from acute I/R injury and also might attenuate cardiac remodeling and heart failure. The mechanisms involved in this cardioprotection by TZDs are multi-factorial and not completely understood. These novel activities of TZDs could benefit type 2 diabetes patients and offer benefits beyond glycemic control. This new knowledge about the cardioprotective effects of TZDs is still limited, and more investigations, especially clinical studies, are required.
Yue
Tian-Li
TL
Department of Investigative and Cardiac Biology, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA 19406, USA. tian-li_yue@gsk.com
D000818:Animals; D002316:Cardiotonic Agents / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000187:drug effects*; D013329:Structure-Activity Relationship; D045162:Thiazolidinediones / Q000737:chemistry / Q000494:pharmacology*; D014157:Transcription Factors / Q000819:agonists* / Q000187:drug effects* / Q000494:pharmacology
D002316:Cardiotonic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D045162:Thiazolidinediones; D014157:Transcription Factors